Robust treatment is the major strategy to cure visceral leishmaniasis. There are number of drugs available in the market for the treatment of this hyper-endemic disease. However the cases of VL are increasing at an alarming rate worldwide. The
main reasons for the re-emergence and spread of disease are the treatment failures due to the evolution of resistant parasites and asymptomatic and PKDL patients. For instance SSG has been abandoned in many regions of India due to critical issues like growth of resistance and toxic-effects of drug. Thus in parallel to the discovery of safe antileishmanial agent it is essential to examine the possibility of generation of resistance against the novel compounds under test. The latter can be done by investigating the efficacy of the antileishmanial agent against resistant strains.
Moreover VL is a disease related to the severe suppression of immune system of the host. Thus it is indispensable that the leishmanicidal agent should exhibit good immunostimulatory properties.
In this context the present study deals with the investigation of antileishmanial agent which could overcome the shortcomings encountered during treatment of VL especially immunosuppression, toxic effects and drug-resistance. The present study examined the immunomodulatory and antileishmanial efficacy of plant extract of Rhodiola imbricata and its two bioactive compounds namely salidroside and rutin.
Two distinct strains of L. donovani presenting different sensitivity towards SSG have been used in the studies to confirm the broad range efficacy of the plant extract and its active compounds. The testing of plant extract and the compounds was initiated with the in vitro studies to check their antileishmanial activity by trypan blue dye exclusion test and cell cycle analysis through PI staining. Further the in vivo potential of plant extract and the compounds was checked in the inbred BALB/c mice in terms of LDU and real-time PCR. Moreover the immune status of the host was analyzed after treatment of the infected animals with HERERI, SAL or RTN through DTH reaction in response to leishmanin antigen, levels of different Th1/Th2 cytokines, population When the levels of expression of genes viz. iNOS and NF-κB were determined in animals infected with either strain, it was found to be down-regulated.
However SAL and RTN increased the expression of these genes in spleen of animals infected with either strain as compared to the untreated infected animals.
The R-strain parasite expresses its resistant behavior by shunting the expression of many genes including iNOS and NF-κB. The latter genes are crucial for generation of NO, ROS and Th1 immune response in the host. The reduction in parasite load
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following treatment with bioactive compounds was accompanied by increase in the expression of these important genes, iNOS and NF-κB not only in S-but also in Rstrain infected animals. This indicated that the exposition of the resistant parasites to the active compounds resulted in reversal of resistance and these compounds can be exploited further in the high-throughput drug screening tests. Hepatomegaly and renal dysfunction are one of the characteristic symptoms during VL infection. The impaired functions of liver and kidney were observed in the infected animals of either strain as the levels of biomarkers of both these organs were noticed to be in the abnormal range. Similar outcome was observed in the infected animals of either strain after SSG and AmB treatment. The SSG treated animals' depicted hepatic disorders while AmB treated animals exhibited renal impairment.
However HERERI, SAL or RTN treatment restored the increased abnormal levels of liver as well as kidney function biomarkers in the infected animals of either strain.
The findings revealed the inert nature of plant extract, SAL and RTN against toxicity of either liver or kidney. In lethal dose studies also, HERERI did not compromise the viability of animals even at the dose of 5 g/kg b.wt.
Summary and Conclusions
164
Further the histological studies of liver, kidney and spleen in the infected animals of either strain revealed the destructive influence of L. donovani infection on these organs. The hepatotoxicity observed in terms of abnormal liver enzymes was also observed at the histological studies after the SSG treatment. Likewise although no effect of AmB was observed on the liver but kidney histology was shown to be damaged. This further supported the hepato-and nephro-toxicity of Furthermore very importantly the study also highlighted the importance of SAL and RTN in drug discovery pipeline in terms of evolution of resistance. The study revealed that the compounds of HERERI are active against both SSG sensitive as well as resistant Leishmania donovani strains. It depicted the broad range efficacy of these compounds and warrants their ability to enter in the armamentarium of the available antileishmanials.
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The following conclusions can be drawn from the observations made in the study: 
4.
No cell cytotoxicity of HERERI, SAL and RTN was documented and the tested agents were found to be more selective against parasites than the human cells.
5.
The administration of HERERI (LD 50 >5g/kg) induced no mortality or behavioral changes in mice.
6. HERERI, SAL and RTN arrested the promastigotes at the sub G 0 /G 1 phase.
RTN was most effective in causing cell cycle arrest in both sensitive and resistant promastigotes.
7.
HERERI, SAL and RTN decreased the parasite burden in liver and spleen of inbred BALB/c mice.
8. HERERI, SAL and RTN heightened the DTH response in infected animals.
Enhanced cell-mediated immunity was generated after SAL or RTN treatment in sensitive as well as resistant strain infected animals.
9.
The immune status was tilted more towards the Th1 type after HERERI, SAL and RTN treatment. SAL and RTN were more efficient in increasing the titres of Th1 cytokines in mice infected with either sensitive or resistant strain.
10.
The population of different sub sets of T cells viz. CD3 + , CD4 + and CD8 + T lymphocytes was found to be expanded after HERERI, SAL or RTN treatment. SAL and RTN were most functional in generating these T cells in animals infected with either strain. Additionally, the plant extract and the active compounds effectually decreased the number of CD19 B cells.
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11. SAL and RTN upregulated the expression of iNOS and NF-κB genes and also increased the reactive oxidative leishmanicidal molecules viz. NO and ROS in animals infected with the either strain.
12.
No treatment related side-effects were diagnosed in HERERI, SAL or RTN treated infected animals as normal levels of biomarkers of kidney and liver functions were assessed along with the normal histology of kidney, liver and spleen ( Fig. 6.1 ).
Future perspectives
In future the studies should be carried out on the higher animal models.
Additionally more studies are required to be done in other species and strains of Leishmania.
